These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 17456513

  • 21. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL, Freidlin B.
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [Abstract] [Full Text] [Related]

  • 22. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O, Houben P, Ihrig K, Ohmann C, Paulus U, Pfistner B, Schwarz G, Strenge-Hesse A, Zettelmeyer U.
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [Abstract] [Full Text] [Related]

  • 23. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR, Shahumyan H.
    Stat Med; 2007 Nov 30; 26(27):4939-57. PubMed ID: 17582801
    [Abstract] [Full Text] [Related]

  • 24. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ, Grobler A, Abdool Karim SS.
    Clin Trials; 2012 Aug 30; 9(4):377-84. PubMed ID: 22610168
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ.
    J Biopharm Stat; 2008 Aug 30; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. An adaptive approach to implementing bivariate group sequential clinical trial designs.
    Todd S.
    J Biopharm Stat; 2003 Nov 30; 13(4):605-19. PubMed ID: 14584711
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
    Huque MF, Alosh M.
    J Biopharm Stat; 2012 Nov 30; 22(1):160-79. PubMed ID: 22204533
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Evaluating co-primary endpoints collectively in clinical trials.
    Li QH.
    Biom J; 2009 Feb 30; 51(1):137-45. PubMed ID: 19219905
    [Abstract] [Full Text] [Related]

  • 35. A general inefficacy interim monitoring rule for randomized clinical trials.
    Freidlin B, Korn EL, Gray R.
    Clin Trials; 2010 Jun 30; 7(3):197-208. PubMed ID: 20423925
    [Abstract] [Full Text] [Related]

  • 36. Comparison of four sequential methods allowing for early stopping of comparative clinical trials.
    Sebille V, Bellissant E.
    Clin Sci (Lond); 2000 May 30; 98(5):569-78. PubMed ID: 10781388
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD, Emerson SS.
    Contemp Clin Trials; 2008 May 30; 29(3):351-8. PubMed ID: 17933592
    [Abstract] [Full Text] [Related]

  • 39. Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes.
    Hu M, Cappelleri JC, Lan KK.
    Clin Trials; 2007 May 30; 4(4):329-40. PubMed ID: 17848494
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.